You are here


About TTC

Primary tabs

The National Cancer Institute, part of the National Institutes of Health (NIH), is the federal government's principal agency for cancer research and training. NCI’s mission is to lead, conduct, and support cancer research across the nation to advance scientific knowledge and help all people to live longer, healthier lives. NCI’s scope of work spans a broad spectrum of cancer research across a variety of disciplines and supports research training opportunities at career stages across the academic continuum. TTC also serves nine other NIH Institutes and Centers.

TTC's Mission is to enable and guide collaboration, invention development and licensing to advance today's discoveries into tomorrow's medical care. One way that we do this is through a committment to excellent customer service.  The TTC is comprised of professionals with diverse legal, scientific, and business/marketing expertise, and most have doctorate-level technical and/or legal training. Our team of technology transfer, invention development, and marketing specialists will apply their specialized training to guide invention reporting, patenting, patent strategy, executing technology transfer agreements, translational development, and marketing.

Our Value-Add

Our customers include:

  • Pharma and biotech companies interested in solving a specific technical issue, tapping into world-class resources or expanding their business through licensing technology from the NIH
  • Investors (angels, venture capital, private equity, etc.) starting a new company or adding to the pipeline of portfolio companies
  • Academics interested in finding a collaborator or research materials
  • Non-profits interested in finding treatment options for patients or to develop NCI technologies
  • NIH Investigators interested in patenting a discovery or in need of resources to develop a technology.

Desired outcomes of partnerships with the NIH are the therapeutics, vaccines, diagnostics, medical devices and research tools that benefit patients worldwide. 

Explore Collaborative and Licensing Opportunities with the NIH


Wednesday, March 23, 2022